mRNA-based dendritic cell vaccines

@article{Benteyn2015mRNAbasedDC,
  title={mRNA-based dendritic cell vaccines},
  author={Daphn{\'e} Benteyn and Carlo Heirman and Aude Bonehill and Kris Thielemans and Karine Breckpot},
  journal={Expert Review of Vaccines},
  year={2015},
  volume={14},
  pages={161 - 176}
}
Cancer immunotherapy has been proposed as a powerful treatment modality. Active immunotherapy aspires to stimulate the patient’s immune system, particularly T cells. These cells can recognize and kill cancer cells and can form an immunological memory. Dendritic cells (DCs) are the professional antigen-presenting cells of our immune system. They take up and process antigens to present them to T cells. Consequently, DCs have been investigated as a means to stimulate cancer-specific T-cell… 
Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications
TLDR
The advancements in DCs are presented as a platform for cancer immunotherapy, emphasizing the technologies used for in vivo targeting of endogenous DCs, ex vivo generated vaccines from peripheral blood monocytes, and induced pluripotent stem cell-derived DCs (iPSC-DCs) to boost antitumoral immunity.
Recent developments of RNA-based vaccines in cancer immunotherapy
TLDR
RNA vaccines are now in early clinical development with promising safety and efficacy outcomes, and the translation capacity and durability of these vaccines can be increased with chemical modifications and sequence engineering.
Neo-Antigen mRNA Vaccines
TLDR
Recent progress in mRNA-based neo-antigen vaccines is comprehensively reviewed, summarizing critical milestones that made it possible to bring the promise of therapeutic cancer vaccines within reach.
Dendritic cell biology and its role in tumor immunotherapy
TLDR
A comprehensive review of DC biology and its role in tumor Immunotherapy aids in the understanding of DCs as the mentors of T cells and as novel tumor immunotherapy cells with immense potential.
Efficient Nanovaccine Delivery in Cancer Immunotherapy.
TLDR
Aside from peptide antigens, antigen-encoding mRNA for cancer immunotherapy delivered by nanovaccine will also be discussed, and the intracellular release of vaccine and cross-presentation of antigen can be fine-tuned via nanovACCine engineering.
An autologous dendritic cell vaccine polarizes a Th-1 response which is tumoricidal to patient-derived breast cancer cells
TLDR
A DC vaccine that is cytotoxic to autologous breast cancer cells in vitro is developed and the tools and technology generated here will be applied to a phase I/IIa clinical trial.
Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy
TLDR
In this review, following a brief overview of the pivotal milestones in the history of cancer immunotherapy, the reader is introduced to the basic immunobiological and pharmacological principles of active cancer Immunotherapy using DCs.
A universal anti‐cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival
TLDR
An MHC‐II mRNA DCs vaccine platform was developed to activate CD4+ T cells and to enhance the anti‐tumor response by DC vaccination against melanoma, and these constructs were able to inhibit tumor growth, and improve mouse survival.
mRNA Cancer Vaccines.
TLDR
Preclinical and clinical data for the different approaches to mRNA cancer vaccines are reviewed, including the transfection of patient-derived T cells with mRNAs encoding chimeric antigen receptors, which allows the T cells to directly recognize a specific antigen expressed on the tumor.
...
...

References

SHOWING 1-10 OF 165 REFERENCES
Cancer immunotherapy via dendritic cells
TLDR
Dendritic cells are an essential target in efforts to generate therapeutic immunity against cancer owing to their ability to control both immune tolerance and immunity.
Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells
TLDR
Various viral and non‐viral gene transfer systems are reviewed, and their distinct characteristics and possible advantages and disadvantages in respect to their use in DC‐based immunotherapy are discussed.
Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy
TLDR
Evidence supporting the implementation of IL-15 DCs in DC-based cancer vaccination regimens is summarized to highlight the necessity to re-design and optimize the current procedures for DC vaccine manufacturing.
Dendritic cell-based cancer gene therapy.
TLDR
In the present review, gene delivery systems for DCs are discussed, as well as the various transgenes used for genetic modification of DCs, which opens new avenues for the development of optimized clinical protocols.
Current approaches in dendritic cell generation and future implications for cancer immunotherapy
TLDR
Recent developments in clinical DC generation, antigen loading methods and immunomonitoring approaches for DC-based trials for tumor-associated antigens, including dendritic cell vaccination, are reviewed.
Manipulating Immune Regulatory Pathways to Enhance T Cell Stimulation
TLDR
This chapter will focus on the cross talk between DCs and T cells mediated by the CD70/CD27 and PD-L1/PD-1 axis as these have been identified as critical pathways in the regulation of immunity versus tolerance.
Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification.
TLDR
The simultaneous delivery of TAA and activation signals is therefore the topic of this review, emphasizing the role of DC in mediating T cell activation and how to manipulate DC for the pill-pose of enhancing tumour immunotherapy.
Directing dendritic cell immunotherapy towards successful cancer treatment.
TLDR
Using dendritic cells for tumor immunotherapy with new approaches that enhance immunogenicity and overcome the regulatory mechanisms underlying peripheral tolerance may be the key to achieving effective and durable anti-tumor immune responses that translate to better clinical outcomes.
Dendritic Cells The Tumor Microenvironment and the Challenges for an Effective Antitumor Vaccination
TLDR
The general characteristics of DCs and different strategies to generate effective antitumor DC vaccines are described and strategies likely to increase the efficacy of DC vaccines by reprogramming the immunosuppressive nature of the tumor microenvironment are described.
Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration.
TLDR
It is demonstrated that optimal induction of antitumor reactivity against the autologous melanocyte differentiation antigen tyrosinase-related protein-2-derived peptide-loaded DC vaccination occurs after s.c. vaccination and correlates with the preferential accumulation of DCs in the T-cell areas of lymph nodes.
...
...